糖尿病对COVID-19死亡率和医院转归的影响,全球视角:一项ONTOP系统评价和荟萃分析

S. Kastora, Manisha Patel, B. Carter, M. Delibegović, P. Myint
{"title":"糖尿病对COVID-19死亡率和医院转归的影响,全球视角:一项ONTOP系统评价和荟萃分析","authors":"S. Kastora, Manisha Patel, B. Carter, M. Delibegović, P. Myint","doi":"10.2139/ssrn.3951144","DOIUrl":null,"url":null,"abstract":"Background: To date, COVID-19 has claimed 4.9 million lives. Diabetes has been identified as an independent risk factor of serious outcomes in people with COVID-19 infection. Whether that holds true across world regions uniformly has not been previously assessed.Methods: This study offers the first ONTOP systematic review and meta-analysis to analyse the collective and geographically stratified mortality, ICU admission, ventilation requirement, illness severity and discharge rate among patients with diabetes. Five databases were searched from inception to 30 th of August 2021. Prospective and retrospective cohort studies, reporting the association between diabetes and one or more COVID-19 hospitalization outcomes, were included. This meta-analysis was registered on PROSPERO, CRD42021278579.Findings: Overall, 158 observational studies were included, with a total of 270212 of participants, median age 59 [53-65 IQR] of who 56.5 % were male. A total of 22 studies originated from EU, 90 from Far East, 16 from Middle East, and 30 from America. Data were synthesised with mixed heterogeneity across outcomes. Pooled results highlighted that patients with diabetes were at a higher risk of COVID-19-related mortality, OR 1.87 [95%CI 1.61, 2.17]. ICU admissions were increased across all studies for patients with diabetes, OR 1.59 [95%CI 1.15, 2.18], a result that was mainly skewed by Far East-originating studies, OR 1.94 [95%CI 1.51, 2.49]. Ventilation requirements were also increased amongst patients with diabetes worldwide, OR 1.44 [95%CI 1.20, 1.73] as well as their presentation with severe or critical condition, OR 2.88 [95%CI 2.29, 3.63]. HbA1C levels under < 70 mmol and metformin use constituted protective factors in view of COVID-19 mortality, while the inverse was true for concurrent insulin use.Interpretation: Whilst diabetes constitutes a poor prognosticator for various COVID-19 infection outcomes, variability across world regions is significant and may skew overall trends.Registration Details: This meta-analysis was registered on PROSPERO, CRD42021278579.Funding Information: No funding was received for the presented work.Declaration of Interests: The authors have no conflict of interest to declare.","PeriodicalId":349944,"journal":{"name":"Preprints with The Lancet","volume":"130 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis\",\"authors\":\"S. Kastora, Manisha Patel, B. Carter, M. Delibegović, P. Myint\",\"doi\":\"10.2139/ssrn.3951144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: To date, COVID-19 has claimed 4.9 million lives. Diabetes has been identified as an independent risk factor of serious outcomes in people with COVID-19 infection. Whether that holds true across world regions uniformly has not been previously assessed.Methods: This study offers the first ONTOP systematic review and meta-analysis to analyse the collective and geographically stratified mortality, ICU admission, ventilation requirement, illness severity and discharge rate among patients with diabetes. Five databases were searched from inception to 30 th of August 2021. Prospective and retrospective cohort studies, reporting the association between diabetes and one or more COVID-19 hospitalization outcomes, were included. This meta-analysis was registered on PROSPERO, CRD42021278579.Findings: Overall, 158 observational studies were included, with a total of 270212 of participants, median age 59 [53-65 IQR] of who 56.5 % were male. A total of 22 studies originated from EU, 90 from Far East, 16 from Middle East, and 30 from America. Data were synthesised with mixed heterogeneity across outcomes. Pooled results highlighted that patients with diabetes were at a higher risk of COVID-19-related mortality, OR 1.87 [95%CI 1.61, 2.17]. ICU admissions were increased across all studies for patients with diabetes, OR 1.59 [95%CI 1.15, 2.18], a result that was mainly skewed by Far East-originating studies, OR 1.94 [95%CI 1.51, 2.49]. Ventilation requirements were also increased amongst patients with diabetes worldwide, OR 1.44 [95%CI 1.20, 1.73] as well as their presentation with severe or critical condition, OR 2.88 [95%CI 2.29, 3.63]. HbA1C levels under < 70 mmol and metformin use constituted protective factors in view of COVID-19 mortality, while the inverse was true for concurrent insulin use.Interpretation: Whilst diabetes constitutes a poor prognosticator for various COVID-19 infection outcomes, variability across world regions is significant and may skew overall trends.Registration Details: This meta-analysis was registered on PROSPERO, CRD42021278579.Funding Information: No funding was received for the presented work.Declaration of Interests: The authors have no conflict of interest to declare.\",\"PeriodicalId\":349944,\"journal\":{\"name\":\"Preprints with The Lancet\",\"volume\":\"130 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Preprints with The Lancet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.3951144\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Preprints with The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3951144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:迄今为止,COVID-19已夺去490万人的生命。糖尿病已被确定为COVID-19感染者严重后果的独立危险因素。这种情况是否在世界各地都适用,此前还没有得到评估。方法:本研究首次进行ONTOP系统评价和meta分析,分析糖尿病患者的集体和地理分层死亡率、ICU入院率、通气要求、病情严重程度和出院率。从成立到2021年8月30日检索了五个数据库。纳入了前瞻性和回顾性队列研究,这些研究报告了糖尿病与一种或多种COVID-19住院结果之间的关联。该荟萃分析注册号为PROSPERO,编号为CRD42021278579。结果:总的来说,158项观察性研究被纳入,共有270212名参与者,中位年龄59岁[53-65 IQR],其中56.5%为男性。来自欧盟的研究有22项,来自远东的有90项,来自中东的有16项,来自美国的有30项。数据的综合结果具有混合异质性。综合结果显示,糖尿病患者与covid -19相关的死亡风险更高,OR为1.87 [95%CI 1.61, 2.17]。在所有研究中,糖尿病患者的ICU入院率均有所增加,OR为1.59 [95%CI 1.15, 2.18],这一结果主要受到远东研究的影响,OR为1.94 [95%CI 1.51, 2.49]。全球范围内糖尿病患者的通气需求也有所增加,OR为1.44 [95%CI 1.20, 1.73],以及出现严重或危重情况的患者,OR为2.88 [95%CI 2.29, 3.63]。考虑到COVID-19死亡率,HbA1C < 70 mmol和使用二甲双胍是保护因素,而同时使用胰岛素则相反。解释:虽然糖尿病是各种COVID-19感染结果的不良预测指标,但世界各地的差异很大,可能会扭曲总体趋势。注册信息:该荟萃分析注册号为PROSPERO, CRD42021278579。经费情况:没有收到提交工作的经费。利益声明:作者无利益冲突需要声明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
Background: To date, COVID-19 has claimed 4.9 million lives. Diabetes has been identified as an independent risk factor of serious outcomes in people with COVID-19 infection. Whether that holds true across world regions uniformly has not been previously assessed.Methods: This study offers the first ONTOP systematic review and meta-analysis to analyse the collective and geographically stratified mortality, ICU admission, ventilation requirement, illness severity and discharge rate among patients with diabetes. Five databases were searched from inception to 30 th of August 2021. Prospective and retrospective cohort studies, reporting the association between diabetes and one or more COVID-19 hospitalization outcomes, were included. This meta-analysis was registered on PROSPERO, CRD42021278579.Findings: Overall, 158 observational studies were included, with a total of 270212 of participants, median age 59 [53-65 IQR] of who 56.5 % were male. A total of 22 studies originated from EU, 90 from Far East, 16 from Middle East, and 30 from America. Data were synthesised with mixed heterogeneity across outcomes. Pooled results highlighted that patients with diabetes were at a higher risk of COVID-19-related mortality, OR 1.87 [95%CI 1.61, 2.17]. ICU admissions were increased across all studies for patients with diabetes, OR 1.59 [95%CI 1.15, 2.18], a result that was mainly skewed by Far East-originating studies, OR 1.94 [95%CI 1.51, 2.49]. Ventilation requirements were also increased amongst patients with diabetes worldwide, OR 1.44 [95%CI 1.20, 1.73] as well as their presentation with severe or critical condition, OR 2.88 [95%CI 2.29, 3.63]. HbA1C levels under < 70 mmol and metformin use constituted protective factors in view of COVID-19 mortality, while the inverse was true for concurrent insulin use.Interpretation: Whilst diabetes constitutes a poor prognosticator for various COVID-19 infection outcomes, variability across world regions is significant and may skew overall trends.Registration Details: This meta-analysis was registered on PROSPERO, CRD42021278579.Funding Information: No funding was received for the presented work.Declaration of Interests: The authors have no conflict of interest to declare.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信